Cylex, Inc., Columbia, MD, announced that an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using its proprietary ImmuKnow immune cell function test was found to identify patients that may be at risk for early acute transplant rejection and unstable kidney function in the first three months following transplantation.
The study, which consisted of 126 kidney transplant patients, was designed to evaluate the association of a number of immune parameters measured prior to kidney transplant with the occurrence of early acute rejection, unstable kidney function and graft outcome following ...